posted on 2005-11-03, 00:00authored byRobert W. Marquis, Ian James, Jin Zeng, Robert E. Lee Trout, Scott Thompson, Attiq Rahman, Dennis S. Yamashita, Ren Xie, Yu Ru, Catherine J. Gress, Simon Blake, Michael A. Lark, Shing-Mei Hwang, Thaddeus Tomaszek, Priscilla Offen, Martha S. Head, Maxwell D. Cummings, Daniel F. Veber
The extension of a previously reported cathepsin K azepanone-based inhibitor template to the
design and synthesis of potent and selective inhibitors of the homologous cysteine protease
cathepsin L is detailed. Structure−activity studies examining the effect of inhibitor selectivity
as a function of the P3 and P2 binding elements of the potent cathepsin K inhibitor 1 revealed
that incorporation of either a P3 quinoline-8-carboxamide or a naphthylene-1-carboxamide led
to increased selectivity for cathepsin L over cathepsin K. Substitution of the P2 leucine of 1
with either a phenylalanine or a β-naphthylalanine also resulted in an increased selectivity
for cathepsin L over cathepsin K. Molecular modeling studies with the inhibitors docked within
the active sites of both cathepsins L and K have rationalized the observed selectivities.
Optimization of cathepsin L binding by the combination of the P3 naphthylene-1-carboxamide
with the P2 β-naphthylalanine provided 15, which is a potent, selective, and competitive
inhibitor of human cathepsin L with a Ki = 0.43 nM.